Management of Osteoporosis in Postmenopausal Breast Cancer Survivors

Authors

Xuezhi Jiang, Department of Obstetrics and Gynecology, Reading Hospital, Reading, PA and Sidney Kimmel Medical College of Thomas Jefferson University, Department of ObGyn, Philadelphia, PA
Peter F Schnatz, Departments of Obstetrics and Gynecology and Internal Medicine, Reading Hospital, Reading, PA and Sidney Kimmel Medical College of Thomas Jefferson University, Department of ObGyn, Philadelphia, PA
Risa Kagan, East Bay Physicians Medical Group, Berkeley, CA and University of California, Department of Obstetrics, Gynecology, and Reproductive Sciences, San Francisco, CA

Document Type

Book

Publication Date

2-2-2017

Abstract

A 55-year-old Caucasian postmenopausal woman with BMI of 22.5 kg/m2 presents to the clinic for follow-up to discuss the results of her recent dual-energy X-ray absorptiometry (DXA) bone mineral density (BMD) scan. She has a personal history of premenopausal early-stage hormone receptor-positive breast cancer at age 47 and a family history of parental hip fracture. Following her initial breast cancer treatment, she received tamoxifen for 5 years (Age 47–52) followed by anastrozole (an aromatase inhibitor) until the current time. The DXA scan reports T-scores of −1.8 at the total hip and −1.6 at the lumbar spine. What would be your preferred management?

Publication Title

Essentials of Menopause Management

First Page

285

Last Page

301

Comments

Book Chapter - pages 285-301

• Print ISBN:978-3-319-42449-1
• Online ISBN:978-3-319-42451-4

Recommended Citation

Jiang, X., Schnatz, P., & Kagan, R. (2017). Management of Osteoporosis in Postmenopausal Breast Cancer Survivors. Essentials of Menopause Management, 285-301. https://doi.org/https://doi.org/10.1007/978-3-319-42451-4_18